Trial Profile
Study on Persistence on Certolizumab and Predictors Thereof in with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial-Spondyloarthritis Patients: Biopure Registry (The BIOlogic aPUlian REgistry)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Apr 2019
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis
- Focus Adverse reactions; Therapeutic Use
- 02 Apr 2019 Results assessing the the effectiveness of certolizumab and identify any predictors of favorable outcome in patients with RA, PsA, or SpA (n=355) published in the Clinical Drug Investigation
- 15 Jul 2018 New trial record
- 16 Jun 2018 Results (n=345) assessing Drug Survival on Certolizumab, presented at the 19th Annual Congress of the European League Against Rheumatism